Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Targeted Biologic Therapies for Allergic Conditions: From Bench to Bedside
share announcement

Targeted Biologic Therapies for Allergic Conditions: From Bench to Bedside

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 1247

Editors

Dr. Antonio Francesco Maria Giuliano

E-Mail Website
Guest Editor
Clinica Medica “A. Murri”, Department of Preventive and Regenerative and Ionian Area (DiMePre-J), University of Bari “Aldo Moro”, AOUC Policlinico Hospital, Bari, Italy
Interests: asthma; allergy; internal medicine; digital health; health-related quality of life; biologics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Maria Teresa Ventura

E-Mail Website
Guest Editor
Medical School, University of Bari “Aldo Moro”, Bari, Italy
Interests: asthma; allergy; internal medicine; digital health; health-related quality of life; biologics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Allergic diseases such as atopic dermatitis, allergic rhinitis, and asthma remain major global health burdens, with  heterogeneous clinical phenotypes and complex immunopathology challenging the development of effective therapies. The advent of biologics has revolutionized treatment strategies, allowing precision targeting of cytokines, cell surface receptors, immune checkpoints, and signaling pathways. However, many clinical gaps remain: identifying which patients benefit most, understanding sex- and gender-specific mechanisms of pathogenesis, overcoming resistance or loss of response, integrating biologics with conventional therapies, and expanding indications beyond asthma and eczema.

This Special Issue of Biomedicines aims to attract contributions that bridge fundamental immunology and translational medicine, with a focus on novel biologic strategies in allergic disease. We welcome high-quality original research and review articles on topics including, but not limited to, novel biologic biomarkers and predictors of response, personalized endotypes, safety and immunogenicity challenges, combinations with small molecules or immunotherapies, and applications in underexplored areas (e.g. professional allergies, food allergies, chronic urticaria). We hope this collection will serve allergists, dermatologists, immunologists, and translational scientists alike by fostering cross-disciplinary insights and accelerating the next wave of biologic innovation in allergic diseases.

Dr. Antonio Francesco Maria Giuliano
Prof. Dr. Maria Teresa Ventura
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biologics
  • allergic disease
  • atopic dermatitis
  • allergic rhinitis
  • asthma
  • precision medicine
  • biomarkers
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1021 KB  
Article
Nasal Cytology Is Useful for Evaluating and Monitoring the Therapeutic Response to Biologics in Chronic Rhinosinusitis with Nasal Polyposis
by Gioia Piatti, Ludovica Battilocchi, Anna Cozzi, Lorenzo Maria Gaini, Mirko Aldè, Lorenzo Pignataro and Sara Torretta
Biomedicines 2026, 14(1), 77; https://doi.org/10.3390/biomedicines14010077 - 30 Dec 2025
Cited by 3 | Viewed by 963
Abstract
Background/Objectives: In recent years, the recognition that type 2 inflammation plays a leading role in CRSwNP has enabled the more tailored treatment of the disease through improved patient endotyping. We studied 45 patients with severe CRSwNP who were treated with dupilumab or [...] Read more.
Background/Objectives: In recent years, the recognition that type 2 inflammation plays a leading role in CRSwNP has enabled the more tailored treatment of the disease through improved patient endotyping. We studied 45 patients with severe CRSwNP who were treated with dupilumab or mepolizumab. The aim was to evaluate the efficacy of these treatments on endoscopic, clinical and patient reported parameters, and to assess whether nasal cytology could be useful for identifying responsive patients and monitoring their response to biologic drugs. Methods: Follow-up visits were scheduled at baseline (T0), and at 3 (T3), 6 (T6), 12 (T12), and 24 months (T24). At each visit, patients underwent blood analysis, nasal endoscopy, and nasal scraping for cytology. They also completed the SNOT-22 questionnaire, a visual analog scale (VAS) for nasal obstruction and smell perception, and the Asthma Control Test (ACT) test in cases of concomitant asthma. Results: Biological therapy demonstrated broad efficacy in disease management, based on both clinical and cytological findings. The Nasal Polyp Score, SNOT-22 questionnaire, VAS scores for nasal obstruction and smell, and ACT score showed progressive improvement. Blood eosinophil counts and total IgE levels also decreased over time (T0 vs. T24: p = 0.008 and p < 0.001, respectively). At nasal cytology, a reduction in eosinophil cell count and in the mixed mast cell–eosinophil pattern during treatment with both biologics were observed (T0 vs. T24: p < 0.001). Positive effects were typically recorded within six months of treatment and were sustained after two years. Conclusions: Although the histological evaluation of infiltrated tissues remains the gold standard for assessing mucosal eosinophilia, nasal cytology appears to be a simpler, non-invasive, and repeatable method for evaluating local eosinophilia. Identifying endotypes and assessing the severity of inflammation are crucial for predicting the efficacy of different treatment options. Full article
(This article belongs to the Special Issue Targeted Biologic Therapies for Allergic Conditions: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop